The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ICML 2019 | CLL trial highlights from 15-ICML

Name: CLL trial highlights from 15-ICML
Uploaded: 2019-06-20T00:00:00.000Z
Duration: 3 min 55 s
Description: Ahmad Alhuraiji, MD, of the Kuwait Cancer Control Center, Kuwait City, Kuwait, discusses three major chronic lymphocytic leukemia (CLL) trials that were presented at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. These include a Swiss trial, CLL14 (NCT02242942), and CLL12 (NCT02863718).

Ahmad Alhuraiji • 20 Jun 2019

ICML 2019

Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax

CLL12 CLL14

Ahmad Alhuraiji, MD, of the Kuwait Cancer Control Center, Kuwait City, Kuwait, discusses three major chronic lymphocytic leukemia (CLL) trials that were presented at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. These include a Swiss trial, CLL14 (NCT02242942), and CLL12 (NCT02863718).

1:33

Work at the Kuwait Cancer Control Center

Ahmad Alhuraiji • 20 Jun 2019

ICML 2019 | CLL trial highlights from 15-ICML

More from Ahmad Alhuraiji

Related Videos